Tirtei E, Campello A, Sciannameo V, Asaftei S, Meazza C, Sironi G
BMC Cancer. 2024; 24(1):747.
PMID: 38898388
PMC: 11186082.
DOI: 10.1186/s12885-024-12498-x.
Carter T, Milic M, McDerra J, McTiernan A, Ahmed M, Karavasilis V
Cancers (Basel). 2020; 12(11).
PMID: 33212978
PMC: 7698576.
DOI: 10.3390/cancers12113408.
Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C
Clin Sarcoma Res. 2015; 4(1):16.
PMID: 25628856
PMC: 4307996.
DOI: 10.1186/2045-3329-4-16.
Sweiss K, Beri R, Shord S
Drug Saf. 2008; 31(11):989-96.
PMID: 18840018
DOI: 10.2165/00002018-200831110-00003.
Brunello A, Basso U, Rossi E, Stefani M, Ghiotto C, Marino D
Drugs Aging. 2007; 24(11):967-73.
PMID: 17953463
DOI: 10.2165/00002512-200724110-00008.
Phase I study of docetaxel plus ifosfamide in patients with advanced cancer.
Marx G, Lewis C, Hall K, Levi J, Ackland S
Br J Cancer. 2002; 87(8):846-9.
PMID: 12373597
PMC: 2376167.
DOI: 10.1038/sj.bjc.6600542.
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Kerbusch T, de Kraker J, Keizer H, Van Putten J, Groen H, Jansen R
Clin Pharmacokinet. 2001; 40(1):41-62.
PMID: 11236809
DOI: 10.2165/00003088-200140010-00004.
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.
Pelgrims J, De Vos F, Van den Brande J, Schrijvers D, Prove A, Vermorken J
Br J Cancer. 2000; 82(2):291-4.
PMID: 10646879
PMC: 2363270.
DOI: 10.1054/bjoc.1999.0917.
6-Day continuous infusion of high-dose ifosfamide with bone marrow growth factors in advanced refractory malignancies.
Brain E, Mita A, Soulie P, Errihani H, Hardy Bessard A, Chaouche M
J Cancer Res Clin Oncol. 1997; 123(4):227-31.
PMID: 9177496
DOI: 10.1007/BF01240320.
A phase II study of every other day high-dose ifosfamide in pediatric brain tumors: a Pediatric Oncology Group Study.
Heideman R, Douglass E, Langston J, Krischer J, Burger P, Kovnar E
J Neurooncol. 1995; 25(1):77-84.
PMID: 8523093
DOI: 10.1007/BF01054726.
Prohibitive toxicity of a dose-intense regime for metastatic neuroblastoma containing ifosfamide, doxorubicin and cisplatin.
Lowis S, Pearson A, Reid M, Craft A
Cancer Chemother Pharmacol. 1993; 31(5):415-8.
PMID: 8431977
DOI: 10.1007/BF00686158.
Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.
Corlett S, Parker D, Chrystyn H
Br J Clin Pharmacol. 1995; 39(4):452-5.
PMID: 7640155
PMC: 1365136.
DOI: 10.1111/j.1365-2125.1995.tb04477.x.
Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.
Boos J, Welslau U, Ritter J, Blaschke G, Schellong G
Cancer Chemother Pharmacol. 1991; 28(6):455-60.
PMID: 1934249
DOI: 10.1007/BF00685822.
Dosing and side-effects of ifosfamide plus mesna.
Brade W, Herdrich K, ARAUJO C
J Cancer Res Clin Oncol. 1991; 117 Suppl 4:S164-86.
PMID: 1795007
DOI: 10.1007/BF01613224.
Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T, Martinelli G, Goldhirsch A, Terrier F, Joss R, Fey M
J Cancer Res Clin Oncol. 1991; 117 Suppl 4:S135-8.
PMID: 1795002
DOI: 10.1007/BF01613218.
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
Cerny T, Graf A, Rohner P, Zeugin T, BRUNNER K, Kupfer A
J Cancer Res Clin Oncol. 1991; 117 Suppl 4:S129-34.
PMID: 1795001
DOI: 10.1007/BF01613217.
Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.
Dechant K, Brogden R, PILKINGTON T, Faulds D
Drugs. 1991; 42(3):428-67.
PMID: 1720382
DOI: 10.2165/00003495-199142030-00006.
